Shouldyou invest in Kenvue?
Kenvue is best suited for investors who want to prioritize safety over growth. It has an excellent portfolio of well-known brands, it's in good shape financially, and it pays a sizable dividend. But it certainly won't match the kinds of highs the top growth stocks reach.
While Kenvue hasn't been available long, it's not an unproven new company. After all, it was previously part of Johnson & Johnson, which has frequently ranked as one of the largest companies by market cap. Now that it's on its own, Kenvue is a major player among consumer goods companies and is the largest pure-play consumer health company.
Even if you don't know much about Kenvue as a company, you're probably familiar with many of its brands. They include:
- Band-Aid.
- Johnson's.
- Listerine.
- Neutrogena.
- Neosporin.
- Nicorette.
- Tylenol.
- Zyrtec.
Because its brands are fairly diversified, Kenvue has a reliable business model that consistently churns out a profit. It's also not overly reliant on any one market. It generates about 50% of its sales in North America and 50% internationally.
The downside to investing in Kenvue is that it's probably not going to grow too significantly. Its brands have established, well-known product lines with a fairly fixed demand. These brands also have stiff competition from white-labeled (generic) products that provide similar quality at more affordable prices.
To Kenvue's credit, it's working on expanding its product offerings by embracing new technology. It launched Neutrogena® Collagen Bank™ in August 2024, a new skincare line aimed at younger consumers. It also announced a five-year collaboration with Microsoft (MSFT -0.44%) in April 2025 to transform its digital operations using artificial intelligence (AI) technology. However, Kenvue stock is still more of a low-risk investment than a potential home run.
